Janux Therapeutics, a clinical-stage biopharmaceutical company, recently announced its third-quarter 2024 financial results and provided a business update. The...

Gilead Sciences reported third-quarter solid 2024 financial results, with a 7% year-over-year increase in total product sales, reaching $7.5...

The DPHARM conference brought together a distinguished panel to discuss the critical role of technology investment in clinical trials....

Viridian Therapeutics, a Nasdaq-listed biopharmaceutical company (VRDN), granted stock options to six new employees on November 1, 2024. These...

The connected drug delivery devices market, currently valued at $4.4 billion, is predicted to experience substantial growth, with a...

The global market for Alzheimer’s drugs is poised for significant growth, projected to reach $9.2 billion by 2030, reflecting...

Acadia Pharmaceuticals has finalized an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million....

Exact Sciences Corp. (Nasdaq: EXAS), a prominent cancer screening and diagnostics company, reported third-quarter 2024 revenue of $709 million,...

At DPHARM 2024, Johnson & Johnson’s representatives, Gordon Gregory III, and Laszlo Vasko, unveiled their transformative “Team of Teams”...

Tempus AI, Inc. (NASDAQ: TEM), a technology company driving AI adoption in precision medicine and patient care, released its...